Suneel Gupta's Insider Trades & SAST Disclosures
Suneel Gupta's most recent trade in Protagonist Therapeutics Inc was a trade of 103,437 Common Stock done at an average price of $46.0 . Disclosure was reported to the exchange on Nov. 25, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Suneel Gupta.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 46.04 per share. | 25 Nov 2024 | 103,437 | 256,174 (0%) | 0% | 46.0 | 4,762,239 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 85,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 25 Nov 2024 | 85,000 | 359,611 (1%) | 0% | 7.8 | 663,000 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.02 per share. | 25 Nov 2024 | 45,000 | 274,611 (1%) | 0% | 8.0 | 360,900 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 25 Nov 2024 | 45,000 | 229,611 (0%) | 0% | 7.4 | 332,100 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 25 Nov 2024 | 30,000 | 286,174 (1%) | 0% | 12.2 | 365,100 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 30,000 | 93,750 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 25 Nov 2024 | 19,191 | 266,983 (0%) | 0% | 45.5 | 873,191 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 450 | 93,300 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 25 Nov 2024 | 450 | 267,433 (0%) | 0% | 12.2 | 5,477 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.53 per share. | 26 Feb 2024 | 4,282 | 183,285 (0%) | 0% | 29.5 | 126,447 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 09 Jan 2024 | 5,000 | 192,567 (0%) | 0% | 7.4 | 36,900 | Common Stock |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 09 Jan 2024 | 5,000 | 187,567 (0%) | 0% | 25 | 125,000 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 5,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Gupta Suneel | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 19,250 | 187,567 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,000 | 152,187 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.07 per share. | 31 May 2023 | 4,150 | 148,037 (0%) | 0% | 26.1 | 108,191 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 123,750 | 123,750 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 20,625 | 138,187 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 40,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 26 Apr 2022 | 40,000 | 117,561 (0%) | 0% | 7.4 | 295,200 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 28 Feb 2022 | 649 | 77,007 (0%) | 0% | 24.3 | 15,758 | Common Stock |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 12,500 | 77,656 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 12,000 | 63,987 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges